MURAL ONCOLOGY PLC
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About MURA
Mural Oncology plc is Ireland-based clinical-stage oncology company. The Company is a biotechnology company focused on using its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer with the goal of delivering meaningful and clinical benefits to people living with cancer. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. The lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational-engineered cytokine fusion protein that selectively binds to the intermediate-affinity interleukin-2 (IL-2) receptor. The Company has also developed engineered therapies targeting the interleukin-18 (IL-18) and interleukin-12 (IL-12) pathways, which have demonstrated therapeutic potential in third-party preclinical and clinical studies.
Find out what a historical investment in MURAL ONCOLOGY PLC would be worth today using our MURA stock calculator.
-
-
-
-
-
-
-
-
-
Ready to start your investing journey with Stake?
Open an accountMURA FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in MURA
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in MURA
on Stake
Buy MURA from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of MURA from only US$10 with fractional shares
